FDA Tries To Preempt Possible False Ad Claims By Requesting PAH Labeling Changes
Executive Summary
FDA has asked sponsors of pulmonary arterial hypertension therapies to add information about the patient populations in which they proved the efficacy of their drug to the indication portion of labeling.